SCHEMBL2515957

SCHEMBL2515957

CCOC(=O)C1CNCC1NC(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 6/20 0.47
▸ PPARG P37231 2/20 0.47
▸ PPARA Q07869 2/20 0.47
▸ POLB P06746 2/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ PKM P14618 1/20 0.44
▸ NR1H4 Q96RI1 1/20 0.44
▸ FAAH O00519 1/20 0.42
▸ ADAM17 P78536 1/20 0.42
▸ TAS1R3 Q7RTX0 1/20 0.41
▸ TAS1R1 Q7RTX1 1/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2515969 0.80 HDAC3 (0.45) EPHX2PPARGPPARAHDAC3HDAC1
SCHEMBL2520107 0.80 EPHX2 (0.46) EPHX2PKMADAM17TAS1R3TAS1R1
SCHEMBL2520347 0.78 USP30 (0.53) EPHX2POLBADAM17
SCHEMBL2516381 0.78 USP30 (0.53) EPHX2POLBADAM17
SCHEMBL17485216 0.74 PKM (0.55) EPHX2POLBPKMHTR2C
SCHEMBL2515972 0.73 SSTR4 (0.47) EPHX2HDAC3HDAC1HDAC2NR1H4
SCHEMBL13110287 0.72 MAPT (0.38) PKMTAS1R3TAS1R1
SCHEMBL10186084 0.72 EPHX2 (0.57) EPHX2PPARGPPARAPOLBHDAC3
SCHEMBL13753069 0.71 EPHX2 (0.63) EPHX2PPARGPPARAHDAC3HDAC1
SCHEMBL641471 0.70 POLB (0.49) EPHX2PPARGPPARAPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034949-B2 Pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-11 — — US disclosed
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-07-19 — — US disclosed
EP-1748980-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2007-02-07 — — EP disclosed
WO-2005115977-A1 PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS TANABE SEIYAKU CO., LTD. (JP) 2005-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167440-A1 Novel pyrrolidine compound and a process for preparing the same CNR1, CNR2, OPRD1 EPHX2 238/4885PPARG 683/4885PPARA 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback